Josh Hardman – The State of the Psychedelic Industry | Webinar February 10th 2026

In 2024, there were high expectations that MDMA-assisted therapy would be approved as an official treatment for post-traumatic stress disorder in the United States, and soon thereafter in Europe. However, the FDA rejected the application. While the study sponsor, Lykos Therapeutics, plans to try again with a new application, several other regulatory approval processes related to the clinical use of psychedelics are also simultaneously underway. Some of these are expected to reach approval as early as this year.

One of the central actors tracking research projects, regulatory processes, commercial activities and patents is analyst Josh Hardman, Founder and Editor of Psychedelic Alpha, provides an update on the current state of the psychedelic medicines field. Drawing on his work tracking psychedelic drug development and policy globally, Hardman surveys recent investment trends, the clinical pipeline and trends therein, lobbying activity and political realities, public perception, and international access models. The talk situates U.S. developments alongside international case studies from Australia, Czechia, Germany, Norway, and Canada, offering a comparative view of how different regulatory and access pathways are unfolding.

As well as providing a kind of ‘state of the union’, this talk also focuses on unresolved questions and ethical considerations shaping the field’s future. These include issues around access and equity, commercial incentives, and the tension between medicalisation and broader reform efforts. Ample time is reserved for Q&A and discussion.

The webinar will take place on Tuesday February 10th at 6PM UTC+2. The event contains a Q&A section and the total length is 2 hours. 

We offer this webinar as a pay what you can event: you can participate without paying, but by paying, you can help us produce more events like this and ensure that we can keep offering them to people regardless of their financial circumstances.

0 € – register here
5–20 € – buy ticket here

If you pay for the ticket, please also remember to register for the webinar via the registration link!

You can also support us by paying our membership fee for 2026. You’ll find our membership products on the main page of our web store. We also accept donations.

About the speaker:

In 2020, Josh Hardman founded Psychedelic Alpha to track developments in the psychedelic medicine field. Since then, he has authored hundreds of analyses of matters related to psychedelic medicine, including drug development milestones, policy reforms, and research findings. He has presented on psychedelic medicine at conferences around the world, and acted as an expert to bodies including UK Parliament and the United States Department of Health and Human Services.